MX2015010023A - Anticuerpos anti-cd83 y su uso. - Google Patents

Anticuerpos anti-cd83 y su uso.

Info

Publication number
MX2015010023A
MX2015010023A MX2015010023A MX2015010023A MX2015010023A MX 2015010023 A MX2015010023 A MX 2015010023A MX 2015010023 A MX2015010023 A MX 2015010023A MX 2015010023 A MX2015010023 A MX 2015010023A MX 2015010023 A MX2015010023 A MX 2015010023A
Authority
MX
Mexico
Prior art keywords
antibodies
prognosis
prophylaxis
bind
diagnosis
Prior art date
Application number
MX2015010023A
Other languages
English (en)
Spanish (es)
Inventor
Ann Seldon Therese
John Munster David
Nigel John Hart Derek
Louise Jones Martina
Phillip MUNRO Trent
Michael Mahler Stephen
Yu Zhou Eunice
D Marks James
Original Assignee
Transbio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transbio Ltd filed Critical Transbio Ltd
Publication of MX2015010023A publication Critical patent/MX2015010023A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2015010023A 2013-02-01 2014-01-31 Anticuerpos anti-cd83 y su uso. MX2015010023A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361759780P 2013-02-01 2013-02-01
PCT/AU2014/000066 WO2014117220A1 (en) 2013-02-01 2014-01-31 Anti-cd83 antibodies and use thereof

Publications (1)

Publication Number Publication Date
MX2015010023A true MX2015010023A (es) 2017-11-17

Family

ID=51261317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010023A MX2015010023A (es) 2013-02-01 2014-01-31 Anticuerpos anti-cd83 y su uso.

Country Status (13)

Country Link
US (3) US9840559B2 (OSRAM)
EP (2) EP3626743A1 (OSRAM)
JP (2) JP6539585B2 (OSRAM)
KR (2) KR102449868B1 (OSRAM)
CN (1) CN105531289B (OSRAM)
AU (1) AU2014213009B2 (OSRAM)
CA (1) CA2899960C (OSRAM)
DK (1) DK2951208T3 (OSRAM)
ES (1) ES2762622T3 (OSRAM)
MX (1) MX2015010023A (OSRAM)
NZ (1) NZ711543A (OSRAM)
PT (1) PT2951208T (OSRAM)
WO (1) WO2014117220A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6539585B2 (ja) * 2013-02-01 2019-07-03 デンドロサイト バイオテック ピーティーワイ リミテッド 抗ｃｄ８３抗体及びその使用
CA2965170A1 (en) * 2014-10-23 2016-04-28 Dendrocyte Biotech Pty Ltd Cd83 binding proteins and uses thereof
CA3074379A1 (en) * 2017-09-13 2019-03-21 Kira Biotech Pty Limited Treatment method
AU2019226101A1 (en) * 2018-02-23 2020-09-17 H. Lee Moffitt Cancer Center And Research Institute Inc. CD83-binding chimeric antigen receptors
EP4004051A4 (en) 2019-07-19 2023-08-23 Oncoresponse, Inc. IMMUNOMODULATORY ANTIBODIES AND METHODS OF USE THEREOF
JP7701908B2 (ja) * 2019-08-16 2025-07-02 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 抗ｃｄ３８キメラ抗原受容体を発現する制御性ｔ細胞
CN117547553A (zh) * 2023-11-21 2024-02-13 中国人民解放军陆军特色医学中心 Cd83+、cd83+pd-l1+间充质干细胞及其制备方法和应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593089A (en) 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4751190A (en) 1985-07-22 1988-06-14 Abbott Laboratories Fluorescence polarization immunoassay and reagents for use therein
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0302894B1 (en) 1986-04-28 1992-11-19 Endotronics Inc. Method of culturing leukocytes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
DE4211351A1 (de) 1992-04-04 1993-10-07 Behringwerke Ag Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung
EP0569141A3 (en) 1992-04-14 1994-10-26 Hybritech Inc Method for inhibiting the growth of multidrug-resistant tumors by antibodies.
US5316920A (en) 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
US5710262A (en) 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
US20080152586A1 (en) 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
US5844094A (en) 1992-09-25 1998-12-01 Commonwealth Scientific And Industrial Research Organization Target binding polypeptide
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6541213B1 (en) 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CA2244326C (en) 1997-08-11 2006-03-28 Shinichi Eda Microparticle enhanced light scattering agglutination assay and microparticle reagents therefor
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6562622B1 (en) 1998-05-08 2003-05-13 Diatech Pty, Ltd Continuous in vitro evolution
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
WO2000042430A1 (en) 1999-01-15 2000-07-20 Medtox Scientific, Inc. Lateral flow test strip
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU781547B2 (en) * 1999-04-14 2005-05-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
JP4264348B2 (ja) 2001-08-20 2009-05-13 プロテオム システムズ リミテッド 診断検査方法および装置
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1480598A4 (en) * 2001-11-21 2006-03-22 Celltech R & D Inc HANDLING CYTOKINE RATES USING CD83 GENE PRODUCTS
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2002950779A0 (en) 2002-08-15 2002-09-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland A method of immunomodulation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1565753A2 (en) 2002-11-21 2005-08-24 The University Of Leicester Bodily fluid markers of tissue hypoxia
AU2003300817A1 (en) * 2002-11-21 2004-06-18 Celltech R And D, Inc. Modulating immune responses
US7169898B2 (en) * 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
CN1822857A (zh) 2003-06-02 2006-08-23 阿莱克申药物公司 去免疫原性抗cd3抗体
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
JP4653109B2 (ja) 2003-11-05 2011-03-16 ロシュ グリクアート アクチェンゲゼルシャフト 高められたＦｃレセプター結合親和性及びエフェクター機能をもつＣＤ２０抗体
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
JP2008523083A (ja) 2004-12-08 2008-07-03 イムノメディクス， インコーポレイテッド 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物
WO2006102720A1 (en) 2005-03-31 2006-10-05 Telethon Institute For Child Health Research Isolation of inhibitor of ires-mediated translation
KR20170086700A (ko) * 2005-04-08 2017-07-26 아르고스 쎄라퓨틱스 인코포레이티드 수지상 세포 조성물 및 방법
EP1945668A4 (en) 2005-08-15 2009-07-22 Arana Therapeutics Ltd SYNTHETIC ANTIBODIES WITH FRAMEWORK REGIONS OF NEUWELTPRIMATEN
WO2007150020A1 (en) * 2006-06-23 2007-12-27 Simon Paul M Targeted immune conjugates
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
EP2207803B1 (en) * 2008-06-25 2013-05-01 Korea Research Institute of Bioscience and Biotechnology Cd9-specific human antibodies
AR074369A1 (es) 2008-11-20 2011-01-12 Genentech Inc Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
JP6539585B2 (ja) 2013-02-01 2019-07-03 デンドロサイト バイオテック ピーティーワイ リミテッド 抗ｃｄ８３抗体及びその使用
CA2965170A1 (en) 2014-10-23 2016-04-28 Dendrocyte Biotech Pty Ltd Cd83 binding proteins and uses thereof
CA3074379A1 (en) 2017-09-13 2019-03-21 Kira Biotech Pty Limited Treatment method

Also Published As

Publication number Publication date
CN105531289A (zh) 2016-04-27
US20200339684A1 (en) 2020-10-29
US20180201681A1 (en) 2018-07-19
US10781255B2 (en) 2020-09-22
EP2951208B1 (en) 2019-11-13
AU2014213009A1 (en) 2015-09-17
CA2899960C (en) 2022-05-03
EP3626743A1 (en) 2020-03-25
KR102449868B1 (ko) 2022-10-04
WO2014117220A1 (en) 2014-08-07
NZ711543A (en) 2020-08-28
US9840559B2 (en) 2017-12-12
JP2019076102A (ja) 2019-05-23
KR20150135250A (ko) 2015-12-02
US11725054B2 (en) 2023-08-15
PT2951208T (pt) 2019-12-30
KR20200120967A (ko) 2020-10-22
JP6539585B2 (ja) 2019-07-03
CA2899960A1 (en) 2014-08-07
EP2951208A1 (en) 2015-12-09
CN105531289B (zh) 2019-02-22
KR102204127B1 (ko) 2021-01-20
AU2014213009B2 (en) 2019-01-03
ES2762622T3 (es) 2020-05-25
DK2951208T3 (da) 2020-01-13
US20150376277A1 (en) 2015-12-31
EP2951208A4 (en) 2016-10-19
JP2016507521A (ja) 2016-03-10

Similar Documents

Publication Publication Date Title
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
PH12021552158A1 (en) Antibodies to icos
EP4245376A3 (en) Antibody molecules to pd-l1 and uses thereof
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
TN2014000438A1 (en) Anti-fcrn antibodies
TWD167955S (zh) 生物感測器之部分
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
PH12016500753A1 (en) Antibodies specific to fcrn
PH12014500483A1 (en) Anti-erbb3 antibodies and uses thereof
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
MX2016014862A (es) Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
MX2015010023A (es) Anticuerpos anti-cd83 y su uso.
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
IL241823B (en) Preparations containing novyi .c and their uses for the treatment of cancerous tumors
MX381841B (es) Anticuerpos anti-jagged y métodos de uso.
EP3747907A3 (en) Methods and compositions for treating and preventing disease associated with avb8 integrin
MX2016014416A (es) Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.
EP3030268A4 (en) Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: KIRA BIOTECH PTY LIMITED

FG Grant or registration
PD Change of proprietorship

Owner name: KIRA BIOTECH PTY LIMITED